Different combination antithrombotic therapy (aspirin, P2Y12 antagonist, OAC and LMWH) for 3,6 or 12 months) + Heart failure regimen (ACE, beta-blocker, MRA) at discharge. This evidence concerns the gene P2RY12 and heart failure.